[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653462":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":14,"studyPopulation":14,"armGroups":22,"interventions":33,"overallOfficials":41,"centralContacts":46,"locations":56,"responsibleParty":82,"collaborators":14,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":14,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":14,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":14,"overallStatus":71,"whyStopped":14,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"King Faisal Specialist Hospital & Research Center","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":14,"otherOutcomes":14},[9,13],{"measure":10,"description":11,"timeFrame":12},"correlations","Establish correlations between FeNO levels and established asthma control markers such as ACT scores, eosinophils, and FEV1%.","6 MONTH",{"measure":11,"description":14,"timeFrame":15},null,"12 MONTH",{"allocation":17,"interventionModel":18,"interventionModelDescription":14,"primaryPurpose":19,"observationalModel":14,"timePerspective":14,"maskingInfo":20},"RANDOMIZED","PARALLEL","HEALTH_SERVICES_RESEARCH",{"masking":21,"maskingDescription":14,"whoMasked":14},"NONE",[23,28],{"label":24,"type":6,"description":25,"interventionNames":26},"Feno based","Registration: Eligible participants will be registered consecutively during clinic visits after obtaining informed consent (and assent where applicable).\n\n* Randomization: As this is an observational study comparing prospective data with historical controls, no randomization will be performed. 2.4 Data Gathering Methods\n* Prospective FeNO Group: Monthly data collection over 3 months including ACT\u002F C-ACT questionnaires, FeNO measurements using portable point-of-care devices, spirometry (FEV1%), and peripheral blood eosinophil counts.\n* Historical Control Group: Extraction of relevant clinical data (ACT\u002FC-ACT scores, spirometry, eosinophil counts, ICS adherence, and exacerbation records) from electronic medical records covering a comparable 3-month timeframe. 2.5 Procedures and Central Laboratories\n* FeNO measurements will be conducted using a validated, portable FeNO device standardized across study sites.\n* Spirometry will be performed according to American Thoracic Society guidelines",[27],"Diagnostic Test: FENO",{"label":29,"type":30,"description":25,"interventionNames":31},"historical based","ACTIVE_COMPARATOR",[32],"Diagnostic Test: PFT",[34,38],{"type":35,"name":36,"description":25,"armGroupLabels":37,"otherNames":14},"DIAGNOSTIC_TEST","FENO",[24],{"type":35,"name":39,"description":25,"armGroupLabels":40,"otherNames":14},"PFT",[29],[42],{"name":43,"affiliation":44,"role":45},"Nariman Alrabie","king Faisal specialized hospital and research center","PRINCIPAL_INVESTIGATOR",[47,52],{"name":48,"role":49,"phone":50,"phoneExt":14,"email":51},"Abrar Barnawi","CONTACT","966551266326","abarnawi1@kfshrc.edu.sa",{"name":53,"role":49,"phone":54,"phoneExt":14,"email":55},"Bader Alshrabi","966561681079","balshrabi@kfshrc.edu.sa",[57,70],{"facility":58,"status":59,"city":60,"state":61,"zip":14,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":14},"King Faisal Sepiclaized Hospital and Research Center","ACTIVE_NOT_RECRUITING","Jeddah","Mecca Region","Saudi Arabia","SA",{"type":65,"coordinates":66},"Point",[67,68],39.18624,21.49012,{"lat":68,"lon":67},{"facility":44,"status":71,"city":60,"state":72,"zip":73,"country":62,"countryCode":63,"cosmosGeoPoint":74,"geoPoint":76,"contacts":77},"RECRUITING","Western Region","21499",{"type":65,"coordinates":75},[67,68],{"lat":68,"lon":67},[78,79,81],{"name":48,"role":49,"phone":50,"phoneExt":14,"email":51},{"name":80,"role":49,"phone":54,"phoneExt":14,"email":55},"bader Alshrabi",{"name":43,"role":45,"phone":14,"phoneExt":14,"email":14},{"type":83,"investigatorFullName":14,"investigatorTitle":14,"investigatorAffiliation":14,"oldNameTitle":14,"oldOrganization":14},"SPONSOR","100653462","this-study-aims-to-compare-asthma-control-in-children-monitored-with-feno-against-a-historical-cohort-without-feno-secondary-objectives-include-evaluating-associations-between-feno-levels-actc-act-scores-eosinophil-counts-fev1-ics-adherence-and-exacerbation-frequency-100653462",false,"NCT07788534","This Study Aims to Compare Asthma Control in Children Monitored With FeNO Against a Historical Cohort Without FeNO. Secondary Objectives Include Evaluating Associations Between FeNO Levels, ACT\u002FC-ACT Scores, Eosinophil Counts, FEV1%, ICS Adherence, and Exacerbation Frequency.","FeNO Fractional Exhaled Nitric Oxide Test as Significant Tool in Enhancing Asthma Treatment Management Among Children","Inclusion Criteria:\n\n* Children aged 6 to 14 years with a physician-diagnosed asthma.\n\n  * Minimum of three months' follow-up at the pediatric respiratory clinic.\n  * Availability of Asthma Control Test (ACT\u002FC-ACT) scores and clinical data\n\nExclusion Criteria:\n\n* Presence of other chronic pulmonary diseases (e.g., cystic fibrosis).\n\n  * Recent respiratory infections within four weeks prior to enrollment.\n  * Current treatment with biologic agents affecting asthma inflammation.","ALL","6 Years","14 Years",{"count":95,"type":96},80,"ESTIMATED","INTERVENTIONAL",[99],"NA","This study aims to evaluate whether incorporating FeNO monitoring into routine pediatric asthma care improves clinical outcomes relative to a historical cohort managed without FeNO",[102],"Asthma Childhood","2026-08-23",{"date":105,"type":106},"2026-08-26","ACTUAL",{"date":108,"type":106},"2025-11-12",{"date":110,"type":96},"2026-11-12",{"name":5,"class":6},2]